

Press Release

Eurocor announces treatment of First Patients in International Randomized Freeride Study

FREEWAY™ drug-eluting balloon used for treatment of de-novo or restenotic lesions in the SFA or Popliteal arteries

Bonn, Germany | Bengaluru, India | January 27, 2012

[Eurocor GmbH](#), an Opto Circuits group company, announced today that the first patients in the Freeride study have been successfully treated with the drug-eluting balloon (DEB) [FREEWAY™](#). The study is lead-managed by Prof. Dr. Karl-Ludwig Schulte, Vascular Center Berlin/Ev. Königin Elisabeth Hospital in Berlin, Germany. The randomized, prospective, multicentre clinical study is being conducted at a total of 25 sites worldwide and involves 280 patients. The aim of the trial is to investigate the rate of clinically driven target lesion revascularization (TLR) using the Paclitaxel-eluting FREEWAY™ balloon in comparison to an uncoated balloon (POBA) in de-novo or restenotic lesions in the Superficial Femoral Artery (SFA) or Popliteal arteries (PI-segment). Patients suffering from occluded, stenotic, reoccluded or restenotic lesions of 4 – 15 cm length will be treated either with a Paclitaxel-eluting balloon (Freeway™) or with POBA. A 6 and 12 month Duplex follow-up will be carried out as well as an angiographic follow-up in a subgroup at 6 months. This is an ongoing study and the first angiographic analysis and results are expected in spring 2013.

Prof. Dr. Schulte commented: “Stenotic or blocked lesions are serious problems, particularly in the SFA and PI-segment. Drug-eluting balloons offer a promising solution by reopening the vessel without leaving a stent; we are therefore looking forward to the results of this study. We hope this will result in fewer complications and less suffering for the patient.”

“We are pleased that the first patients have successfully been treated and are doing well. This is a key milestone for the company in its path to prove safety and efficacy of drug-eluting balloons also as a treatment for the SFA and PI-segment” said Dr. Rembert Pogge von Strandmann, Director Clinical Department, Eurocor. “We trust that our DEB technology platform used on the FREEWAY™ balloon offers another significant therapeutic advantage for patients.”

A study overview was presented on the occasion of the [Leipzig Interventional Course \(LINC\) 2012](#) during the Eurocor Symposium on January 26th, 4:30 – 6:00 pm, Main Arena. For more details visit: www.leipzig-interventional-course.de and www.eurocor.de.

About Eurocor GmbH:

Eurocor is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor provides interventional physicians with innovative coronary stent technologies and special cardiovascular and endovascular devices, manufactured in Bonn. Products are indicated for

Press Release

minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Extensive research and development, close clinician collaboration, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for balloon catheter drug delivery with high patient compliance. One heartbeat ahead™ – with innovative products such as DIOR® and FREEWAY™.

Eurocor GmbH is a subsidiary of Opto Eurocor Healthcare Ltd. and is part of the Opto Circuits Group.

For more information, please visit www.eurocor.com

About: [Opto Circuits \(India\) Ltd.](#)

Headquarters: Bengaluru, Karnataka, India

BSE: 532391 | NSE: OPTOCIRCUI

Opto Circuits (India) Ltd. (OCI) is a multinational medtech company in the business of design, development, manufacture and marketing of healthcare equipment and medical interventional products. The product profile includes USFDA-listed, CE-marked cardiac and vital signs monitoring systems, anesthesia and respiratory care equipment, automated external defibrillators, stents, PTA balloons, catheters, body implants and consumables. Some of OCI's well-known brands are [Cardiac Science](#), [Criticare](#), [Eurocor](#), [Ormed](#), [Mediaid](#) and [Unetixs](#). The company's key markets are North America, Europe and BRIC countries.

Media Contact

Anna Beck/Nidhi Thind Phone: 080 28521040-42 Email: media@optoindia.com